- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02843607
Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
By enrolling patients with kidney cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and nature killer (NK) cells for advanced kidney cancer.
The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510665
- Cancer Institute in Fuda cancer hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
- Body tumor 1-6, the maximum tumor length < 5 cm
- KPS ≥ 70, lifespan > 6 months
- Platelet count ≥ 80×109/L,white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion Criteria:
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cryosurgery and NK immunotherapy
In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months).
The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
|
Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
|
ACTIVE_COMPARATOR: Cryosurgery
In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors.
The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
|
Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relief degree
Time Frame: 3 months
|
It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST)
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progress free survival(PFS)
Time Frame: 1 year
|
1 year
|
Overall survival(OS)
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NK-kidney
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Renal Cell Cancer
-
NewLink Genetics CorporationCompletedMetastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedMetastatic Renal Cell Carcinoma | Metastatic Kidney CancerFrance
-
National Cancer Institute (NCI)RecruitingClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Soft Tissues | Metastatic Malignant Neoplasm in the Viscera and other conditionsUnited States, Puerto Rico
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Metastatic Renal Cell Cancer | Stage IV Renal Cell Cancer AJCC v7United States
-
Duke UniversityCompletedMetastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
University of ChicagoNational Cancer Institute (NCI)RecruitingMetastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell CancerUnited States
-
National Cancer Institute (NCI)TerminatedClear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Stage II Renal Cell Cancer AJCC v7 | Stage I Renal Cell Cancer AJCC v6 and v7United States
Clinical Trials on Cryosurgery
-
Khon Kaen UniversityTerminatedHuman Papillomavirus Clearance at 12 MonthsThailand
-
Larkin Community HospitalWithdrawn
-
Milton S. Hershey Medical CenterCompletedSeborrheic KeratosisUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedBreast Cancer RecurrentChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)TerminatedPain | Kidney Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Melanoma (Skin)United States
-
photonamic GmbH & Co. KGCompleted
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Fuda Cancer Hospital, GuangzhouJinan University GuangzhouCompleted
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMetastatic Esophageal CancerChina
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedNon-small Cell Lung Cancer MetastaticChina